Previous 10 | Next 10 |
Summary Davis Selected Advisers 13F portfolio value increased from $14.06B to $14.71B this quarter. They increased Meta Platforms, Amazon.com, and Markel while reducing Cigna, JD.com, and Coupang. The top three positions are Berkshire Hathaway, Wells Fargo, and Capital One Financial...
The FDA has rejected a marketing application for a biosimilar version of cancer therapy bevacizumab that Viatris ( NASDAQ: VTRS ) submitted, the U.S. drugmaker's partner in India Biocon, announced. Bevacizumab is the active ingredient of Roche's ( OTCQX:RHHBY ) ( OTCQX:RHHBF )...
Summary Viatris and Organon are what can currently be described as "deep value plays" in the pharmaceutical sector. They face largely similar challenges, but on closer inspection are quite different companies. While I have already reported on Viatris' ever-changing portfolio, in this ar...
Advent International's Zentiva generics business and Bain-backed drugmaker Stada Arzneimittel are evaluating offers for Viatris Inc.'s ( NASDAQ: VTRS ) consumer-health assets, which could see €3billion in a sale. The European over-the-counter portfolio is attracting possib...
A panel of the European Medicines Agency (EMA) recommended granting approval to Viatris ( NASDAQ: VTRS ) drug Dapagliflozin Viatris to treat type 2 diabetes mellitus, heart failure and chronic kidney disease. Dapagliflozin Viatris is a generic of AstraZeneca's ( NASDAQ: ...
Summary In the fourth quarter of 2022, the Miller Income Strategy returned 11.68%, while the benchmark ICE BofA US High Yield Index was up 3.98%. While China’s reopening stimulates aggregate global demand, it also unclogs global supply chains, thereby easing pricing pressures aro...
Summary Investing is a process of learning and growing; I look back at the knowledge I have gained so far on my journey. My three main blunders were thinking in dividends only, paying any price and losing patience. In 2022, my articles have returned an average of 8.84% vs. the S&...
Summary As a leader in various therapeutic areas, the company's total revenue was $7,042 million in the third quarter of 2022, up 12.5% quarter-on-quarter. Gilead will be required to make royalties of 3% on future sales of Biktarvy and bictegravir-containing medicines up to the 4th quar...
If you want your portfolio to cut you a consistent check to use as passive income every quarter from here on out, you'll need to load up on high-quality dividend stocks that'll stand the test of time. And if you want that passive income to come from a decent return, the recent pullback in the...
Summary Viatris has seen a disappointing performance since its 2019 mega tie-up. Sales and EBITDA have fallen a bit, as leverage has fallen a bit further. The overall performance has been disappointing, but valuations have compressed further, leaving me wondering why recent deals ha...
News, Short Squeeze, Breakout and More Instantly...
2024-07-26 12:25:00 ET The late comedian Rodney Dangerfield was famous for his catchphrase, "I don't get no respect." Does Dangerfield's line apply to some stocks today? Absolutely. Three Motley Fool contributors think they've found surprisingly underrated pharmaceutical stocks to b...
NORTHAMPTON, MA / ACCESSWIRE / July 23, 2024 / No country can make every medicine people need, and no medicine is made in every country. If a country or region relies on supply only from within their region and they experience a crisis, there is a risk people won't get the medicines they need, w...
NORTHAMPTON, MA / ACCESSWIRE / July 18, 2024 / Viatris is a global healthcare company focused on bringing high-quality medicines to patients through a hybrid approach that bridges the traditional divide between generics and brands, combining the best of both, to more holistically address healthc...